tirzepatide (Zepbound)
Adjunctive therapy • Brands: ZEPBOUND
Last reviewed: 2026-02-12
General information
- Primary label indications include: Chronic weight management (with diet and exercise) in adults with obesity or overweight with weight-related comorbidities (label).
- Class: Adjunctive therapy
- Common US brands: ZEPBOUND
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2026-02-12
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Weekly injectable dual [[GIP]]/[[GLP-1]] receptor agonist (tirzepatide) indicated for chronic weight management (with diet and exercise). It has no FDA-approved psychiatric indications but may be considered in psychiatric populations for cardiometabolic risk reduction with careful monitoring for mood changes (label/clinical).
Metabolism & Half‑life
- Metabolism: Proteolytic cleavage of the peptide backbone
- Half‑life: Single-dose mean 120 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- ZEPBOUND (tirzepatide) injection prescribing information — DailyMed (2026)
- Tirzepatide once weekly for the treatment of obesity — New England Journal of Medicine (2022)
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes — New England Journal of Medicine (2021)
- Therapeutic management of atypical antipsychotic-related metabolic dysfunctions using GLP-1 receptor agonists: a systematic review — Experimental and Therapeutic Medicine (2023)